BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

BioMarin drug acquired in buyout misses goal in rare disease study

Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More

StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls

BMRN Stock Down on Mixed Results From Rare Disease Therapy Study

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

BioMarin (BMRN) Is Down 6.3% After Mixed Phase 3 BMN 401 Results in ENPP1 Deficiency

BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint

1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today